论文部分内容阅读
胶质瘤是一种最常见的颅内原发性恶性肿瘤。近年来,胶质瘤的病毒治疗成为研究热点。现在应用条件性复制腺病毒(CRAds)靶向治疗胶质瘤得到广泛研究和认可,CRAds经过基因工程修饰后可在肿瘤细胞中特异性复制,获得很强的感染性、细胞毒性和获得预期的转基因表达,从而溶解肿瘤细胞消除肿瘤。由于现在的CRAds治疗胶质瘤都是透过向动物模型中注射的方式,所以药物分布不均限制了CRAds的疗效。干细胞对胶质瘤有内在趋向性,应用干细胞作为细胞载体荷载CRAds治疗胶质瘤,特别是追踪播散的胶质瘤细胞成为研究热点。
Glioma is one of the most common primary intracranial malignancies. In recent years, the treatment of glioma virus has become a research hot spot. Nowadays, targeted therapy of glioma with conditional replication adenovirus (CRAds) has been extensively studied and approved. CRAds can be specifically replicated in tumor cells after being genetically modified to obtain strong infectivity, cytotoxicity and obtain expected Transgene expression, thus dissolving tumor cells to eliminate the tumor. Because of the current CRAds treatment of gliomas through injection into animal models, poor drug distribution limits the efficacy of CRAds. Stem cells have an intrinsic tendency to glioma. The application of stem cells as a cell carrier to treat glioma by loading CRAds, especially tracking of disseminated glioma cells has become a hot topic.